Physician profile
Xavier Villa
NPI 1659381853
$888.95
in general payments reported to CMS, 2019-2025
10 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.80 · 2020: $6.57 · 2021: $99.78 · 2022: $108 · 2023: $101 · 2024: $125 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $124.97 | 2024 | Voquezna |
| Novo Nordisk INC | $124.47 | 2025 | Wegovy |
| Alcresta Therapeutics, INC. | $120.68 | 2025 | Relizorb |
| Genzyme Corporation | $107.95 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.86 | 2022 | |
| Boston Scientific Corporation | $100.87 | 2023 | Exalt Model D |
| Abbvie INC. | $99.78 | 2021 | |
| Qol Medical, LLC | $76.03 | 2019 | |
| Intercept Pharmaceuticals, INC. | $19.77 | 2019 | |
| Travere Therapeutics, INC. | $6.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xavier Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.